Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS) and Strongbridge Biopharma plc is fair to Xeris shareholders. Upon closing, Xeris shareholders will exchange each share of Xerix common stock they own for 1 share of the combined company. Current Xeris shareholders are expected to own approximately 60% of the combined company.

Halper Sadeh encourages Xeris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

The investigation concerns whether Xeris and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Xeris shareholders; and (2) disclose all material information necessary for Xeris shareholders to adequately assess and value the merger consideration. On behalf of Xeris shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Halper Sadeh encourages Xeris shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005847/en/